GLUC Stock Poised for Growth After Preferred Share Restructuring—Here's What Changed

Glucose Health, Inc. Closes Major Capital Overhaul at 85% Premium to Current Trading Price

In a significant move signaling confidence in future growth, Glucose Health, Inc. (OTC: GLUC) has successfully completed a sweeping preferred stock conversion that fundamentally reshapes the company’s balance sheet. The deal, finalized on December 23, 2025, converted 97% of dividend-bearing convertible preferred shares into common stock at $0.25 per share—representing an impressive 85% premium over GLUC’s current market valuation. The remaining 3% of accrued dividend shares were converted at $0.10 per share, effectively wiping preferred liabilities off the books entirely.

A Simpler, Debt-Free Capital Structure

What makes this conversion noteworthy is what it accomplishes: Glucose Health is now effectively a debt-free company with a streamlined capital structure. The restructuring eliminated all dividend-bearing preferred share classes and related balance-sheet liabilities, leaving only 1,000 non-convertible voting preferred shares held by board members Christopher J. Jemapete and Edmund J. Burke for governance purposes.

Post-conversion, the company now boasts 27.3 million issued and outstanding common shares, with 10.5 million shares in the public float eligible for open-market trading. On a fully-diluted basis—accounting for 2.2 million employee warrants—total common shares equal 29.5 million. This cleaner structure should enhance liquidity for GLUC shares trading over-the-counter and remove barriers that institutional investors often encounter with complex preferred share hierarchies.

What the Numbers Tell Us

The conversion involved two distinct tranches: 6.67 million preferred shares converted at the $0.25 premium price, while 188,014 preferred shares representing accumulated dividends converted at $0.10 each. CEO Mark Schaftlein framed the move as the newly-appointed board’s priority initiative, describing it as essential for positioning the company “with a much simpler, less cumbersome capital structure” while eliminating future dividend liabilities.

Products Gaining Market Traction

The timing of this financial restructuring coincides with accelerating product momentum. Glucose Health’s flagship brand GlucoDown—formulated to support healthy glucose metabolism—has accumulated nearly 12,000 consumer reviews on Amazon and maintains top ratings across all flavors. The product is now stocked in the diabetic-care sections of select Walgreens and CVS locations nationwide.

The company’s newer brand, Fiber Up, positions GLUC directly in the soluble fiber supplement category, competing head-to-head with established players like Metamucil. This market segment has proven increasingly attractive as dietary fiber consumption remains a national public-health priority. The U.S. Department of Health & Human Services and U.S. Department of Agriculture have formally designated dietary fiber as a “nutrient of public health concern” due to widespread under-consumption across American populations.

Building Scale in Metabolic Wellness

With consumer interest in dietary fiber and metabolic-wellness solutions rising, Glucose Health’s product roadmap includes upcoming formats: soluble fiber sodas, waters, nutrition bars, and other convenient delivery mechanisms. The company estimates its shareholder base has grown to exceed 1,000 individual investors, reflecting growing awareness of its brands across major national retailers and leading online marketplaces.

All products are manufactured in the United States and distributed through major retailers, anchoring Glucose Health’s market position in the growing soluble fiber segment. The preferred stock conversion, combined with this product expansion and distribution network, positions GLUC for the next growth phase in the consumer-health space.

The Bottom Line

By eliminating preferred share complexity and associated dividend obligations, Glucose Health has cleared the structural deck. Whether this capital reorganization can translate into share-price appreciation remains the key question for OTC traders and retail investors following GLUC. The company’s momentum in fiber nutrition products and metabolic-wellness positioning suggests management is betting on accelerating market adoption to drive that next leg higher.